Report Code: CMI31871

Published Date: September 2023

Pages: 220+

Category: Pharmaceuticals

Report Snapshot

CAGR: 3.7%

Source: CMI

Study Period: 2024-2033
Fastest Growing Market: Asia-Pacific
Largest Market: Europe

Major Players

  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Samsung Bioepis Co. Ltd.
  • Merck & Co. Inc.
  • Others

Exclusive, in-depth market intelligence can help you increase your Revenue.

Download Sample Pdf

Reports Description

As per the current market research conducted by the CMI Team, the global Enbrel Market is expected to record a CAGR of 3.7% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 15.5 billion. By 2032, the valuation is anticipated to reach USD 23.2 billion.

The Enbrel market encompasses pharmaceutical products aimed at treating autoimmune diseases, with a focus on rheumatoid arthritis, psoriatic arthritis, and plaque psoriasis. It operates within the biopharmaceutical sector, characterized by complex biologic drugs.

Key trends include an increased emphasis on personalized medicine, ongoing advancements in biotechnology, and the growing availability of biosimilar alternatives to Enbrel, enhancing affordability and competition. Additionally, the integration of telemedicine and digital healthcare tools has revolutionized patient care and medication adherence, shaping the evolving landscape of the Enbrel market.

Enbrel Market – Significant Growth Factors

The Enbrel Market presents significant growth opportunities due to several factors:

  • Escalating Autoimmune Disorder Incidence: The surging prevalence of autoimmune conditions, such as rheumatoid arthritis and psoriasis, serves as a potent catalyst for the Enbrel market. These chronic illnesses often necessitate prolonged biological treatments, increasing the demand for medications like Enbrel.
  • Biotechnology Progression: Ongoing advancements in biotechnology, encompassing refined drug delivery systems and precisely targeted therapies, offer prospects for enhancing Enbrel’s efficacy and user-friendliness, thereby attracting a broader patient demographic.
  • Biosimilar Competition: The emergence of biosimilar versions of Enbrel has introduced competition, potentially lowering treatment costs and increasing accessibility for patients, while driving innovation in the market.
  • Personalized Medicine: The trend towards personalized medicine allows for tailored Enbrel treatment plans, optimizing patient outcomes and reducing adverse effects, thus attracting more patients and healthcare providers to the market.
  • Digital Health and Telemedicine: The integration of telemedicine and digital health tools has expanded patient access, providing opportunities for remote monitoring, improved patient engagement, and adherence to Enbrel treatment regimens.
  • Global Expansion: Opportunities for market growth lie in expanding Enbrel’s availability in emerging markets with unmet medical needs, as well as exploring new indications and potential combination therapies, further diversifying its applications and patient base.

Enbrel Market – Mergers and Acquisitions

The Enbrel Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their Product offerings and profitability. Some notable examples of mergers and acquisitions in the Enbrel Market include:

  • In the year 2023, Amgen made a significant move by acquiring Horizon Therapeutics, a deal valued at $27.8 billion. This strategic acquisition granted Amgen entry into the realm of rare disease medications offered by Horizon, which included Tepezza, a drug designed for the treatment of thyroid eye disease. However, the transaction also encompassed Krystexxa, one of Horizon’s products utilized in the management of chronic refractory gout—a direct competitor to Amgen’s Enbrel.
  • In 2019, AbbVie orchestrated a monumental acquisition when it secured Allergan for a staggering $63 billion. This strategic move provided AbbVie with access to Humira, a pharmaceutical powerhouse renowned as the world’s top-selling drug. Humira serves as a treatment for a spectrum of autoimmune disorders, and its consistent success has gradually eroded Enbrel’s market share over the years.
  • In 2015, Pfizer executed a pivotal acquisition, bringing Hospira under its corporate umbrella. This strategic move provided Pfizer with a valuable entry into the biosimilar arena, marked by Hospira’s robust biosimilar portfolio. Among these offerings was Inflectra, a biosimilar medication directly competing with Enbrel in the market. This acquisition significantly bolstered Pfizer’s presence in the biologics and biosimilars sector, allowing it to engage in the increasingly competitive landscape of biopharmaceuticals, including Enbrel and its alternatives.

These mergers and partnerships have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Enbrel Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.


Enbrel Market Pharmaceutical Stability & Storage Services Market Antibacterial Drugs Market
CAGR 12.6% (Approx) CAGR 5.3% (Approx) CAGR 5.6% (Approx)
USD 548.9 Billion by 2032 USD 3.2 Billion by 2032 USD 67.9 Billion by 2032

Enbrel Market – Significant Threats

The Enbrel Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:

  • Competition from Biosimilars: The introduction of biosimilar versions of Enbrel poses a substantial threat. As these biosimilars gain regulatory approval and enter the market, they can offer more affordable alternatives to Enbrel, potentially leading to market share erosion.
  • Patent Expirations: Enbrel’s patent protections have been a key factor in its market dominance. As these patents expire, it opens the door for generic and biosimilar competition, which can lead to pricing pressures and reduced revenue for the brand.
  • Regulatory Challenges: The regulatory landscape for biologics like Enbrel can be complex. Changes in regulations, safety concerns, or adverse events can lead to increased scrutiny and potential market restrictions.
  • Healthcare Cost Containment: Efforts to control healthcare costs, including drug pricing, by governments and payers can impact the affordability and accessibility of Enbrel, potentially limiting its market growth.
  • Emerging Therapies: Ongoing research and development efforts may lead to the discovery of new and more effective treatments for autoimmune diseases. These innovations could divert patient interest and market share away from Enbrel.
  • Market Saturation: In some regions, the Enbrel market may already be saturated, leaving limited room for further expansion. This could result in fiercer competition among pharmaceutical companies for a stagnant or declining customer base.
  • Adverse Events and Safety Concerns: Any safety issues or adverse events associated with Enbrel can significantly impact its market reputation and demand.
  • Economic Factors: Economic downturns or changes in healthcare reimbursement policies can affect patients’ ability to afford Enbrel, leading to decreased demand.
  • Global Health Crises: Unexpected events like pandemics or other global health crises can disrupt the pharmaceutical supply chain, leading to shortages and impacting the availability of Enbrel.
  • Patient Preference Shifts: Patient preferences can change over time, and if they increasingly favor alternative treatments or therapies, it can reduce Enbrel’s market share.

Report Scope

Feature of the Report Details
Market Size in 2023 USD 16.2 Billion
Projected Market Size in 2032 USD 23.2 Billion
Market Size in 2022 USD 15.5 Billion
CAGR Growth Rate 3.7% CAGR
Base Year 2023
Forecast Period 2024-2033
Key Segment By Product, Application and Region
Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends
Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America
Buying Options Request tailored purchasing options to fulfil your requirements for research.

Category-Wise Insights

By Product:

  • Brands Drugs: Brand drugs in the Enbrel market refer to patented, original medications, like Enbrel itself, used to treat autoimmune diseases. Current trends include the rise of biosimilar competition, increased emphasis on personalized treatment plans, and growing adoption of digital health tools for remote monitoring and patient engagement, reshaping market dynamics.
  • Biosimilar Drugs: Biosimilar drugs are highly similar versions of biologic medications like Enbrel, offering cost-effective alternatives. In the Enbrel market, biosimilars are gaining prominence due to patent expirations, driving competition, reducing costs, and expanding patient access. Regulatory pathways and advancements in biosimilar development are key trends shaping this market segment.

By Application

  • Rheumatoid Arthritis: Rheumatoid arthritis, a persistent autoimmune ailment causing joint inflammation and discomfort, shapes the Enbrel market. Key trends encompass heightened competition from biosimilars, a growing utilization of biologics for early-stage treatment, and an accentuated focus on personalized medicine. Moreover, the integration of digital health tools and telemedicine has elevated patient involvement and Enbrel accessibility.
  • Psoriatic Arthritis: Psoriatic arthritis, which afflicts individuals with psoriasis by impacting their joints, highlights a notable trend within the Enbrel market. Enbrel (etanercept) has gained prominence as a biological therapy for this condition due to its efficacy in alleviating joint symptoms and managing skin lesions. This efficacy surge has spurred heightened adoption and market expansion.
  • Ankylosing Spondylitis: Ankylosing Spondylitis, a persistent inflammatory ailment impacting spinal and joint health, stands out as a significant trend within the Enbrel market. The rising acknowledgement of Enbrel as an exceptionally effective therapeutic choice for addressing Ankylosing Spondylitis has gained traction, delivering relief from distressing symptoms and an improved standard of living for those afflicted. Enbrel’s well-documented success has sparked a noteworthy surge in demand among individuals in pursuit of alleviation from the burdens of this incapacitating condition.
  • Juvenile Idiopathic Arthritis: Juvenile Idiopathic Arthritis (JIA), a pediatric autoimmune disorder characterized by joint inflammation, showcases a distinct trend in the Enbrel market. Its growing application as a treatment for JIA in pediatric patients is fueled by Enbrel’s effectiveness and FDA approval for this purpose. This trend underscores the increasing commitment to enhancing the quality of life for young autoimmune disease sufferers.

Global Enbrel Market 2023–2032 (By Billion)

Enbrel Market – Regional Analysis

The Enbrel Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:

  • North America: In the Enbrel market, North America comprises the United States and Canada. Trends in this region include a strong demand for Enbrel due to a high prevalence of autoimmune diseases, growing biosimilar competition, and an emphasis on personalized medicine. The adoption of digital health tools and telemedicine is also rising, improving patient access and engagement.
  • Europe: In the European Enbrel market, trends encompass a mature market with substantial biosimilar competition, pushing for affordability. There’s an increasing focus on early-stage biologic treatments, personalized medicine, and regulatory changes affecting pricing and access.
  • Asia-Pacific: The Asia-Pacific Enbrel market reflects rising demand for autoimmune disease treatments, with countries like Japan, China, and India driving growth. Biosimilar competition is emerging, and efforts to improve healthcare access and affordability are notable trends, along with the adoption of digital health solutions.
  • LAMEA: In the LAMEA region’s Enbrel market, trends include improving access to biologic treatments, growing awareness of Enbrel’s efficacy, and a rising prevalence of autoimmune diseases. However, challenges related to healthcare infrastructure and regulatory hurdles persist, impacting market dynamics.

Global Enbrel Market 2023–2032 (By Product)

Competitive Landscape – Enbrel Market

The Enbrel Market is highly competitive, with a large number of manufacturers and others operating globally. Some of the key players in the market include:

  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Samsung Bioepis Co. Ltd.
  • Merck & Co. Inc.
  • Sandoz International GmbH (a subsidiary of Novartis)
  • Mylan N.V. (now Viatris Inc.)
  • Biogen Inc.
  • AbbVie Inc.
  • Johnson & Johnson
  • Others

These companies operate in the market through various strategies such as application innovation, mergers and acquisitions, and partnerships.

New entrants aiming to tap into the Enbrel market have predominantly focused on biosimilar development and innovation. Biosimilar manufacturers like Samsung Bioepis and Mylan (now Viatris) have made strides in creating more affordable alternatives to Enbrel. They’ve invested in R&D and received regulatory approvals to enter the market.

However, key players like Amgen and Pfizer, with their established brands of Enbrel, continue to dominate the market. Their long-standing presence, strong marketing efforts, and extensive clinical data have solidified their positions. While biosimilar competition grows, these incumbents maintain a significant market share, aided by brand loyalty and physician trust.

The Enbrel Market is segmented as follows:

By Product

  • Brands Drugs
  • Biosimilar Drugs

By Application

  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Ankylosing Spondylitis
  • Juvenile Idiopathic Arthritis

Regional Coverage:

North America

  • U.S.
  • Canada
  • Mexico
  • Rest of North America


  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Rest of Asia Pacific

The Middle East & Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa

Latin America

  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

  • Chapter 1. Preface
    • 1.1 Report Description and Scope
    • 1.2 Research scope
    • 1.3 Research methodology
      • 1.3.1 Market Research Type
      • 1.3.2 Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1 Global Enbrel Market, (2024 – 2033) (USD Billion)
    • 2.2 Global Enbrel Market: snapshot
  • Chapter 3. Global Enbrel Market – Industry Analysis
    • 3.1 Enbrel Market: Market Dynamics
    • 3.2 Market Drivers
      • 3.2.1 Escalating Autoimmune Disorder Incidence
      • 3.2.2 Biotechnology Progression
      • 3.2.3 Biosimilar Competition
      • 3.2.4 Personalized Medicine
      • 3.2.5 Digital Health and Telemedicine
      • 3.2.6 Global Expansion.
    • 3.3 Market Restraints
    • 3.4 Market Opportunities
    • 3.5 Market Challenges
    • 3.6 Porter’s Five Forces Analysis
    • 3.7 Market Attractiveness Analysis
      • 3.7.1 Market Attractiveness Analysis By Product
      • 3.7.2 Market Attractiveness Analysis By Application
  • Chapter 4. Global Enbrel Market- Competitive Landscape
    • 4.1 Company market share analysis
      • 4.1.1 Global Enbrel Market: Company Market Share, 2022
    • 4.2 Strategic development
      • 4.2.1 Acquisitions & mergers
      • 4.2.2 New Product launches
      • 4.2.3 Agreements, partnerships, collaboration, and Joint Ventures
      • 4.2.4 Research and development and Regional expansion
    • 4.3 Price trend analysis
  • Chapter 5. Global Enbrel Market – Product Analysis
    • 5.1 Global Enbrel Market Overview: By Product
      • 5.1.1 Global Enbrel Market Share, By Product, 2022 and – 2033
    • 5.2 Brands Drugs
      • 5.2.1 Global Enbrel Market by Brands Drugs, 2024 – 2033 (USD Billion)
    • 5.3 Biosimilar Drugs
      • 5.3.1 Global Enbrel Market by Biosimilar Drugs, 2024 – 2033 (USD Billion)
  • Chapter 6. Global Enbrel Market – Application Analysis
    • 6.1 Global Enbrel Market Overview: By Application
      • 6.1.1 Global Enbrel Market Share, By Application, 2022 and – 2033
    • 6.2 Rheumatoid Arthritis
      • 6.2.1 Global Enbrel Market by Rheumatoid Arthritis, 2024 – 2033 (USD Billion)
    • 6.3 Psoriatic Arthritis
      • 6.3.1 Global Enbrel Market by Psoriatic Arthritis, 2024 – 2033 (USD Billion)
    • 6.4 Ankylosing Spondylitis
      • 6.4.1 Global Enbrel Market by Ankylosing Spondylitis, 2024 – 2033 (USD Billion)
    • 6.5 Juvenile Idiopathic Arthritis
      • 6.5.1 Global Enbrel Market by Juvenile Idiopathic Arthritis, 2024 – 2033 (USD Billion)
  • Chapter 7. Enbrel Market – Regional Analysis
    • 7.1 Global Enbrel Market Regional Overview
    • 7.2 Global Enbrel Market Share, by Region, 2022 & – 2033 (USD Billion)
    • 7.3. North America
      • 7.3.1 North America Enbrel Market, 2024 – 2033 (USD Billion)
        • North America Enbrel Market, by Country, 2024 – 2033 (USD Billion)
    • 7.4 North America Enbrel Market, by Product, 2024 – 2033
      • 7.4.1 North America Enbrel Market, by Product, 2024 – 2033 (USD Billion)
    • 7.5 North America Enbrel Market, by Application, 2024 – 2033
      • 7.5.1 North America Enbrel Market, by Application, 2024 – 2033 (USD Billion)
    • 7.6. Europe
      • 7.6.1 Europe Enbrel Market, 2024 – 2033 (USD Billion)
        • Europe Enbrel Market, by Country, 2024 – 2033 (USD Billion)
    • 7.7 Europe Enbrel Market, by Product, 2024 – 2033
      • 7.7.1 Europe Enbrel Market, by Product, 2024 – 2033 (USD Billion)
    • 7.8 Europe Enbrel Market, by Application, 2024 – 2033
      • 7.8.1 Europe Enbrel Market, by Application, 2024 – 2033 (USD Billion)
    • 7.9. Asia Pacific
      • 7.9.1 Asia Pacific Enbrel Market, 2024 – 2033 (USD Billion)
        • Asia Pacific Enbrel Market, by Country, 2024 – 2033 (USD Billion)
    • 7.10 Asia Pacific Enbrel Market, by Product, 2024 – 2033
      • 7.10.1 Asia Pacific Enbrel Market, by Product, 2024 – 2033 (USD Billion)
    • 7.11 Asia Pacific Enbrel Market, by Application, 2024 – 2033
      • 7.11.1 Asia Pacific Enbrel Market, by Application, 2024 – 2033 (USD Billion)
    • 7.12. Latin America
      • 7.12.1 Latin America Enbrel Market, 2024 – 2033 (USD Billion)
        • Latin America Enbrel Market, by Country, 2024 – 2033 (USD Billion)
    • 7.13 Latin America Enbrel Market, by Product, 2024 – 2033
      • 7.13.1 Latin America Enbrel Market, by Product, 2024 – 2033 (USD Billion)
    • 7.14 Latin America Enbrel Market, by Application, 2024 – 2033
      • 7.14.1 Latin America Enbrel Market, by Application, 2024 – 2033 (USD Billion)
    • 7.15. The Middle-East and Africa
      • 7.15.1 The Middle-East and Africa Enbrel Market, 2024 – 2033 (USD Billion)
        • The Middle-East and Africa Enbrel Market, by Country, 2024 – 2033 (USD Billion)
    • 7.16 The Middle-East and Africa Enbrel Market, by Product, 2024 – 2033
      • 7.16.1 The Middle-East and Africa Enbrel Market, by Product, 2024 – 2033 (USD Billion)
    • 7.17 The Middle-East and Africa Enbrel Market, by Application, 2024 – 2033
      • 7.17.1 The Middle-East and Africa Enbrel Market, by Application, 2024 – 2033 (USD Billion)
  • Chapter 8. Company Profiles
    • 8.1 Amgen Inc.
      • 8.1.1 Overview
      • 8.1.2 Financials
      • 8.1.3 Product Portfolio
      • 8.1.4 Business Strategy
      • 8.1.5 Recent Developments
    • 8.2 Pfizer Inc.
      • 8.2.1 Overview
      • 8.2.2 Financials
      • 8.2.3 Product Portfolio
      • 8.2.4 Business Strategy
      • 8.2.5 Recent Developments
    • 8.3 Novartis AG
      • 8.3.1 Overview
      • 8.3.2 Financials
      • 8.3.3 Product Portfolio
      • 8.3.4 Business Strategy
      • 8.3.5 Recent Developments
    • 8.4 Samsung Bioepis Co. Ltd.
      • 8.4.1 Overview
      • 8.4.2 Financials
      • 8.4.3 Product Portfolio
      • 8.4.4 Business Strategy
      • 8.4.5 Recent Developments
    • 8.5 Merck & Co. Inc.
      • 8.5.1 Overview
      • 8.5.2 Financials
      • 8.5.3 Product Portfolio
      • 8.5.4 Business Strategy
      • 8.5.5 Recent Developments
    • 8.6 Sandoz International GmbH (a subsidiary of Novartis)
      • 8.6.1 Overview
      • 8.6.2 Financials
      • 8.6.3 Product Portfolio
      • 8.6.4 Business Strategy
      • 8.6.5 Recent Developments
    • 8.7 Mylan N.V. (now Viatris Inc.)
      • 8.7.1 Overview
      • 8.7.2 Financials
      • 8.7.3 Product Portfolio
      • 8.7.4 Business Strategy
      • 8.7.5 Recent Developments
    • 8.8 Biogen Inc.
      • 8.8.1 Overview
      • 8.8.2 Financials
      • 8.8.3 Product Portfolio
      • 8.8.4 Business Strategy
      • 8.8.5 Recent Developments
    • 8.9 AbbVie Inc.
      • 8.9.1 Overview
      • 8.9.2 Financials
      • 8.9.3 Product Portfolio
      • 8.9.4 Business Strategy
      • 8.9.5 Recent Developments
    • 8.10 Johnson & Johnson
      • 8.10.1 Overview
      • 8.10.2 Financials
      • 8.10.3 Product Portfolio
      • 8.10.4 Business Strategy
      • 8.10.5 Recent Developments
    • 8.11 Others.
      • 8.11.1 Overview
      • 8.11.2 Financials
      • 8.11.3 Product Portfolio
      • 8.11.4 Business Strategy
      • 8.11.5 Recent Developments
List Of Figures

Figures No 1 to 20

List Of Tables

Tables No 1 to 52

Report Methodology

In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:

Preliminary Data Mining

On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.

Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.

Statistical Model

Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.

Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.

Some of the variables taken into account for forecasting are as follows:

• Industry drivers and constraints, as well as their current and projected impact

• The raw material case, as well as supply-versus-price trends

• Current volume and projected volume growth through 2030

We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.

Primary Validation

This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.

Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.

All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:

• Market leaders

• Suppliers of raw materials

• Suppliers of raw materials

• Buyers.

The following are the primary research objectives:

• To ensure the accuracy and acceptability of our data.

• Gaining an understanding of the current market and future projections.

Data Collection Matrix

Perspective Primary research Secondary research
  • Manufacturers
  • Technology distributors and wholesalers
  • Company reports and publications
  • Government publications
  • Independent investigations
  • Economic and demographic data
  • End-user surveys
  • Consumer surveys
  • Mystery shopping
  • Case studies
  • Reference customers

Market Analysis Matrix

Qualitative analysis Quantitative analysis
  • Industry landscape and trends
  • Market dynamics and key issues
  • Technology landscape
  • Market opportunities
  • Porter’s analysis and PESTEL analysis
  • Competitive landscape and component benchmarking
  • Policy and regulatory scenario
  • Market revenue estimates and forecast up to 2030
  • Market revenue estimates and forecasts up to 2030, by technology
  • Market revenue estimates and forecasts up to 2030, by application
  • Market revenue estimates and forecasts up to 2030, by type
  • Market revenue estimates and forecasts up to 2030, by component
  • Regional market revenue forecasts, by technology
  • Regional market revenue forecasts, by application
  • Regional market revenue forecasts, by type
  • Regional market revenue forecasts, by component

Prominent Player

  • Amgen Inc.
  • Pfizer Inc.
  • Novartis AG
  • Samsung Bioepis Co. Ltd.
  • Merck & Co. Inc.
  • Sandoz International GmbH (a subsidiary of Novartis)
  • Mylan N.V. (now Viatris Inc.)
  • Biogen Inc.
  • AbbVie Inc.
  • Johnson & Johnson
  • Others


The key factors driving the Market are Escalating Autoimmune Disorder Incidence, Biotechnology Progression, Biosimilar Competition, Personalized Medicine, Digital Health and Telemedicine And Global Expansion.

The “Product” category dominated the market in 2022.

The key players in the market are Amgen Inc., Pfizer Inc., Novartis AG, Samsung Bioepis Co. Ltd., Merck & Co. Inc., Sandoz International GmbH (a subsidiary of Novartis), Mylan N.V. (now Viatris Inc.), Biogen Inc., AbbVie Inc., Johnson & Johnson, Others.

“Europe” had the largest share in the Enbrel Market.

The global market is projected to grow at a CAGR of 3.7% during the forecast period, 2023-2032.

The Enbrel Market size was valued at USD 15.5 Billion in 2022.












What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • Free 25% or 40 hours of customisation.
  • Free post-sale service assistance.
  • 15% discount on your next purchase.
  • Dedicated account Associate .
  • Permission to print the report.
  • Service guarantee available.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • Free 35% or 60 hours of customisation.
  • Free post-sale service assistance.
  • 25% discount on your next purchase.
  • Service guarantee available.
  • Personalised market brief by author.
  • Permission to print the report.
  • Report in your Language.
  • PDF, Excel and Power Point.
  • Can be accessible by unlimited users.
  • Free 40% or 80 hours of customisation.
  • Free post-sale service assistance.
  • 30% discount on your next purchase.
  • Permission to print the report.
  • Dedicated account manager.
  • Service guarantee available.
  • Report in your Language.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
  • 15% discount on your next purchase.
  • Free 20% or 10 hours of customisation.
  • In-Depth Company Profiles.
  • SWOT Analysis.
  • Identify your Competitors.
  • Recent Development Analysis.
  • Competitor Pricing Strategies.
  • Competitor Marketing Strategies.
  • Competitor Positioning and Messaging.
  • Competitor Product’s Strengths.
  • Free 20% or 10 Hours of Customisation.
  • 15% Discount on your Next Purchase.
  • Upgradable to other licenses.
  • PDF Format.
  • Permission to Print the Report.

Want to customize this report?